Breakthrough Psychosis and Long-Acting Injectable Antipsychotics

“Breakthrough” of psychosis despite good compliance antipsychotics medication for a long time is major obstacle to the treatment schizophrenia, whether mechanism caused by dopamine hypersensitivity or insufficient dose antipsychotics. Researchers advocating “Dopamine Supersensitivity Psychosis” (DSP) emphasize avoid excessive inhibition 2 receptors from beginning treatment. On other hand, researchers “Breakthrough on Antipsychotic Maintenance Medication” (BAMM) in which recurs due continuous administration without non-adherence argue that should be increased enhance therapeutic effect. In patients using long-acting injection (LAI), non-compliance can ruled out. We believe treating non-affective psychosis, it necessary continuously maintain lowest possible optimal considering side effects second-generation and cycle stage formulation such as LAI.